|
Synonyms: R-1450 | RG-1450 | Ro-4909832
Compound class:
Antibody
Comment: Gantenerumab targets aggregated forms of human amyloid β (Aβ) proteins Aβ42 and Aβ40. This is in contrast to solanezumab which targets soluble Aβ.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein sequence analysis reveals that gantenerumab is likely to be clone #7.9.H7 in patent US7794719 [1]. |
| No information available. |
Summary of Clinical Use  |
| May be useful in the treatment of Alzheimer's disease [3]. In phase 1 trials treatment caused reduced brain amyloid β levels, but was associated with the unwanted side effect of vasogenic edema. Phase 3 trial is underway with results expected in 2015. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01760005 | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. | Phase 2/Phase 3 Interventional | Washington University School of Medicine | ||
